Background: Abiraterone acetate (AA) is a potent, selective androgen (CYP17) biosynthesis inhibitor, which showed to improve overall survival (HR = 0.646) in mCRPC patients progressing after docetaxel. In this retrospective analysis we assessed the PFS and OS safety in patients affected with mCRPC progressing after chemotherapy, treated in the normal clinical practice, in several Italian Oncologic Units.
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective analysis of progression-free (PFS) and overall survival (OS) in the “Real Life” / Fabbri, M. A.; Santini, D.; Cortesi, E.; Gamucci, T.; Marchetti, Paolo; Longo, F.; Angelini, F.; Sperduti, I.; Milano, Annalisa; Pellegrino, A.; Nelli, F.; Primi, F.; Raffaele, R.; Mancini, M. L.; Quadrini, S.; Giuli, A.; Ruggeri, E. M.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - ELETTRONICO. - 26:Suppl 6(2015), pp. 1-1. (Intervento presentato al convegno 17th National Congress of Medical Oncology tenutosi a Roma Italy nel 23-25 Ottobre 2015) [10.1093/annonc/mdv341.23].
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective analysis of progression-free (PFS) and overall survival (OS) in the “Real Life”
D. Santini;E. Cortesi;MARCHETTI, PAOLO;MILANO, ANNALISA;
2015
Abstract
Background: Abiraterone acetate (AA) is a potent, selective androgen (CYP17) biosynthesis inhibitor, which showed to improve overall survival (HR = 0.646) in mCRPC patients progressing after docetaxel. In this retrospective analysis we assessed the PFS and OS safety in patients affected with mCRPC progressing after chemotherapy, treated in the normal clinical practice, in several Italian Oncologic Units.| File | Dimensione | Formato | |
|---|---|---|---|
|
Fabbri_Abstract-F23-Abiraterone_2015.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
35.68 kB
Formato
Adobe PDF
|
35.68 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
